CompletedNot Applicable

Acute Kidney Injury in Critical COVID-19: Outcomes and Risks

Turkey (Türkiye)238 participantsStarted 2022-07-01

Plain-language summary

This retrospective observational study aims to determine the incidence of acute kidney injury (AKI) associated with COVID-19, risk factors, and effects on mortality for intensive care unit patients. Data from 238 COVID-19 patients monitored in the Anesthesiology and Reanimation Intensive Care Unit of Ankara University Ibni Sina Hospital between January 1, 2021 and January 1, 2022 were retrospectively reviewed. Patients were divided into two groups according to the level of renal damage (with and without AKI). Those with AKI were staged per the KDIGO criteria (Stage 1-2-3). Demographic data, comorbidities, Charlson comorbidity indexes, Acute Physiology and Chronic Health Evaluation scores, laboratory results, and mortality data were examined. The data obtained were compared between the groups. The findings may help improve clinical awareness and guide management strategies in intensive care unit patients with COVID-19 at risk of AKI

Who can participate

Age range

18 Years

Sex

ALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Age 18 years or older * Hospitalized patients with COVID-19 confirmed by PCR test * Required follow-up in the intensive care unit between January 1, 2021 and January 1, 2022 Exclusion Criteria: * Patients with end-stage renal disease (ESRD) * History of renal transplantation * Intensive care unit stay shorter than 48 hours

Questions worth asking your doctor

Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.

1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?

Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.

Questions for the trial coordinator

The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.

1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?

A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.

What they're measuring

Intensive care unit mortality

Timeframe: From ICU admission until in-hospital death or ICU discharge, whichever occurs first, assessed up to 90 days.

Trial details

NCT IDNCT07089693

SponsorAnkara University

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2022-07-30

View on ClinicalTrials.gov More COVID -19 trials